STOCK TITAN

Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Aytu BioPharma (NASDAQ:AYTU) announced its participation in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit on March 29, 2022, at 11:00 a.m. ET. The panel will focus on managing clinical trials for rare diseases during and after COVID-19. Aytu is a pharmaceutical company dedicated to developing treatments for rare, pediatric-onset disorders. Their product line includes medications for ADHD and allergy treatment, and they are advancing their therapeutic pipeline, including AR101 for Vascular Ehlers-Danlos Syndrome, a condition with no existing treatments.

Positive
  • None.
Negative
  • None.

ENGLEWOOD, CO / ACCESSWIRE / March 22, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that management will participate in a panel discussion titled, "Managing Clinical Trials for Rare Diseases During & After COVID-19," during the Cantor Fitzgerald Virtual Rare Orphan Disease Summit on Tuesday, March 29, 2022 at 11:00 a.m. ET.

If you have interest in participating in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit, please contact your Cantor Fitzgerald representative.

About Aytu BioPharma, Inc.

Aytu BioPharma is a pharmaceutical company with a portfolio of commercial prescription therapeutics and consumer health products, and a growing therapeutics pipeline focused on treating rare, pediatric-onset disorders. The company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal® ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency. Aytu is also building a therapeutic pipeline, which includes AR101 (enzastaurin), a PKCβ inhibitor in development for the treatment of vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disease typically diagnosed in childhood resulting in high morbidity and a significantly shortened lifespan, and for which there are no currently approved treatments. AR101 has received Orphan Drug designation from the U.S. Food and Drug Administration and the European Medicines Agency. To learn more, please visit aytubio.com.

Contact:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

SOURCE: Aytu BioPharma, Inc.



View source version on accesswire.com:
https://www.accesswire.com/692801/Aytu-BioPharma-to-Participate-in-the-Cantor-Fitzgerald-Virtual-Rare-Orphan-Disease-Summit

FAQ

What event is Aytu BioPharma participating in on March 29, 2022?

Aytu BioPharma will participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit.

What topics will be discussed at the summit involving Aytu BioPharma?

The summit will address managing clinical trials for rare diseases during and after COVID-19.

What is the significance of the AR101 therapy by Aytu BioPharma?

AR101 is being developed for Vascular Ehlers-Danlos Syndrome, a rare genetic disease with no current treatments.

What products does Aytu BioPharma offer?

Aytu BioPharma offers products for ADHD, allergy treatments, and fluoride-based vitamin formulations for children.

Where can I find more information about Aytu BioPharma?

More information can be found on their website at aytubio.com.

AYTU BioPharma, Inc.

NASDAQ:AYTU

AYTU Rankings

AYTU Latest News

AYTU Stock Data

8.74M
5.98M
2.44%
34.04%
3.13%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
DENVER